Trek Financial LLC Has $992,000 Position in Danaher Co. (NYSE:DHR)

Trek Financial LLC raised its stake in Danaher Co. (NYSE:DHR) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,321 shares of the conglomerate’s stock after purchasing an additional 1,275 shares during the period. Trek Financial LLC’s holdings in Danaher were worth $992,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of DHR. Gilbert & Cook Inc. grew its stake in Danaher by 2.5% in the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares during the last quarter. Grimes & Company Inc. grew its position in shares of Danaher by 0.6% in the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after purchasing an additional 43 shares during the last quarter. Dakota Community Bank & Trust NA increased its stake in shares of Danaher by 16.4% during the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after purchasing an additional 45 shares during the period. Howard Capital Management Group LLC lifted its holdings in Danaher by 4.1% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 48 shares during the last quarter. Finally, Spinnaker Trust boosted its stake in Danaher by 1.2% in the 4th quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock valued at $988,000 after purchasing an additional 50 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Trading Down 8.3 %

NYSE DHR opened at $181.42 on Monday. The company has a market cap of $129.66 billion, a price-to-earnings ratio of 34.36, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. Danaher Co. has a twelve month low of $165.17 and a twelve month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The business’s fifty day moving average is $209.99 and its 200 day moving average is $233.73.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the business earned $2.09 EPS. As a group, sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.71%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DHR. Wells Fargo & Company dropped their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. The Goldman Sachs Group upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, March 21st. Royal Bank of Canada restated an “outperform” rating and set a $277.00 target price (down previously from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Citigroup dropped their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Raymond James reissued a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.